Comparative Evaluation of Different Marketed Brands of Antidiabetic Tablets: A Comprehensive Review

Diabetes mellitus is a chronic metabolic condition marked by sustained hyperglycemia due to impairments in insulin production, insulin action, or both. It is a significant global health challenge with a swiftly escalating prevalence internationally. The World Health Organization identifies diabetes as a primary contributor to morbidity and death, especially in low- and middle-income nations. Oral antidiabetic agents, particularly Metformin, are commonly employed as first-line treatment in the management of type 2 diabetes mellitus owing to their effectiveness, safety, and cost-efficiency. The existence of several marketed brands of antidiabetic pills prompts significant concerns about pharmaceutical quality, pharmacological equivalence, and interchangeability. This research seeks to assess several marketed brands of antidiabetic pills by examining physicochemical factors, dissolving characteristics, and bioequivalence tests. Evidence from numerous research shows that although most brands conform with pharmacopeial requirements, slight changes in formulation and manufacturing procedures may impact drug release patterns. Nevertheless, these variances often remain within acceptable parameters and do not substantially influence treatment results. The analysis underscores the necessity of ongoing quality control, regulatory oversight, and comparative assessment to guarantee the safety, effectiveness, and uniformity of commercial formulations. It also encourages the use of cost-effective generic pharmaceuticals as viable alternatives to branded treatments in diabetes control.